HCP
STLN

Holt Capital Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Holt Capital Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.7K Hold
29,534
– – 0.01% 153
2025
Q4 		$105K Buy
+29,534
New +$110K 0.01% 151

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holt Capital Partners's STLN Position: Q1 2026 in Review

Holt Capital Partners held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q1 2026 at 29,534 shares worth $90.7K. The position accounts for 0.01% of the portfolio, ranked #153.

Holt Capital Partners first reported a position in STLN in Q4 2025 and has held it in 2 quarters since. The position peaked at $105K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Holt Capital Partners held 29,534 shares of Starling Oncology Institute, Inc. Common Stock worth $90.7K as of Q1 2026.
  • Holt Capital Partners left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up 0.01% of Holt Capital Partners's portfolio in Q1 2026, its #153 holding.
  • Holt Capital Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 2 quarters since.
  • Holt Capital Partners's Starling Oncology Institute, Inc. Common Stock position peaked at $105K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Holt Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.